Should alectinib or ceritinib be given as first line therapy for ALK positive non-small cell lung cancer patients instead of crizotinib?

2017 ◽  
Vol 6 (S6) ◽  
pp. S1010-S1013 ◽  
Author(s):  
Godefridus J. Peters ◽  
Ittai B. Muller ◽  
Elisa Giovannetti
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Small Cell ◽  
Small Cell Lung ◽  
First Line ◽  
Lung Cancer Patients ◽  
First Line Therapy ◽  
Line Therapy ◽  
Alk Positive

Outcome of Surgical Resection as a First Line Therapy in T3 Non-small Cell Lung Cancer Patients

2013 ◽  
Vol 37 (11) ◽  
pp. 2574-2580 ◽  
Author(s):  
Tomoyoshi Takenaka ◽  
Masakazu Katsura ◽  
Yasunori Shikada ◽  
Sadanori Takeo
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Surgical Resection ◽  
Small Cell ◽  
Small Cell Lung ◽  
First Line ◽  
Lung Cancer Patients ◽  
First Line Therapy ◽  
Line Therapy

Checkpoints inhibitors in first line therapy of metastatic non-small cell lung cancer patients

2016 ◽  
Vol 5 (S7) ◽  
pp. S1443-S1448
Author(s):  
Luis E. Raez ◽  
Christian Rolfo ◽  
Mauricio Mahave ◽  
Christian Caglevic
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
First Line ◽  
Lung Cancer Patients ◽  
First Line Therapy ◽  
Line Therapy
Sign in / Sign up

Export Citation Format

Share Document